Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

Rami S. Komrokji, Jeffrey E. Lancet, Arlene S. Swern, Nianhang Chen, Jennifer Paleveda, Richard Lush, Hussain I. Saba, Alan F. List

Blood (2012) 120 (17): 3419–3424.

https://doi.org/10.1182/blood-2012-03-415661

Published: 2012

Journal Articles

Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities

Nikhil C. Munshi, M.D., Saem Lee, B.A., Suman Kambhampati, M.D., Abid Mohiuddin, M.D., Michal Rose, M.D., Caroline Behler, M.D., Andrew Han, B.A., Yvonne Efebera, M.D., Antoun Houranieh, RPh., M.S., Ph.D., Mary T. Brophy, M.D., Abraham Zimelman, M.D., Rao H Prabhala, Ph.D., Hussain I. Saba, M.D, Ph.D, Catherine Klein, M.D., Paulette Mehta, M.D, MPH, Teresa Hayes, M.D., David Roodman, M.D, Ph.D, Alan K. Lichtenstein, M.D.

Blood (2010) 116 (21): 3061.

https://doi.org/10.1182/blood.V116.21.3061.3061

Published: 2010

Journal Articles

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Hagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, Xuelin Huang, Susan O'Brien, Jorge Cortes, Stefan Faderl, Carlos Bueso-Ramos, Farhad Ravandi, Zeev Estrov, Alessandra Ferrajoli, William Wierda, Jianqin Shan, Jan Davis, Francis Giles, Hussain I. Saba, Jean-Pierre J. Issa

Blood (2006) 109 (1): 52–57.

https://doi.org/10.1182/blood-2006-05-021162

Published: 2006

Journal Articles

Response Rates of Phase 2 and Phase 3 Trials of Decitabine (DAC) in Patients with Myelodysplastic Syndromes (MDS).

Hussain I. Saba, MD, PhD, Michael Lübbert, MD, PhD, P.W. Wijermans, MD

Blood (2005) 106 (11): 2515.

https://doi.org/10.1182/blood.V106.11.2515.2515

Published: 2005

Journal Articles

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar): Presented in part at the American Society of Hematology meeting held in San Diego, CA, December 1997.

Ranjana Advani, Hussain I. Saba, Martin S. Tallman, Jacob M. Rowe, Peter H. Wiernik, Joseph Ramek, Kathleen Dugan, Bert Lum, Jenny Villena, Eric Davis, Elisabeth Paietta, Manuel Litchman, Branimir I. Sikic, Peter L. Greenberg

Blood (1999) 93 (3): 787–795.

https://doi.org/10.1182/blood.V93.3.787

Published: 1999

Journal Articles

Anti-Heparin Activity of Lysosomal Cationic Proteins from Polymorphonuclear Leukocytes

HUSSAIN I. SABA, M.D., HAROLD R. ROBERTS, M.D., JOHN C. HERION, M.D.

Blood (1968) 31 (3): 369–380.

https://doi.org/10.1182/blood.V31.3.369.369

Published: 1968

NARROW

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Response Rates of Phase 2 and Phase 3 Trials of Decitabine (DAC) in Patients with Myelodysplastic Syndromes (MDS).

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar): Presented in part at the American Society of Hematology meeting held in San Diego, CA, December 1997.

Anti-Heparin Activity of Lysosomal Cationic Proteins from Polymorphonuclear Leukocytes

Email alerts

ASH Publications

American Society of Hematology

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Response Rates of Phase 2 and Phase 3 Trials of Decitabine (DAC) in Patients with Myelodysplastic Syndromes (MDS).

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar): Presented in part at the American Society of Hematology meeting held in San Diego, CA, December 1997.

Anti-Heparin Activity of Lysosomal Cationic Proteins from Polymorphonuclear Leukocytes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only